T2 Biosystems to Attend Upcoming Investor Conferences
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
T2 Biosystems (NASDAQ:TTOO), a leader in rapid sepsis pathogen and antibiotic resistance gene detection, has announced its participation in two upcoming investor conferences in August 2024:
- The Canaccord Genuity Annual Growth Conference in Boston, MA, where management will host a fireside chat on August 14, 2024, at 10:30am ET.
- The Sidoti Micro-Cap Conference, with virtual participation and a management presentation scheduled for August 15, 2024, at 1:00pm ET.
Interested parties can access live and recorded webcasts of these presentations on the "Investors" section of T2 Biosystems' website at www.t2biosystems.com.
Details
News Market Reaction – TTOO
The recorded move for TTOO in the trading session of this news was -2.78%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
LEXINGTON, Mass., Aug. 01, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced plans to participate in two upcoming investor conferences in August 2024:
- Canaccord Genuity Annual Growth Conference in Boston, Massachusetts. Management is scheduled to host a fireside chat on Wednesday, August 14, 2024, at 10:30am ET.
- Sidoti Micro-Cap Conference, virtual participation. Management is scheduled to present on Thursday, August 15, 2024, at 1:00pm ET.
Interested parties may access live and recorded webcasts of the presentations on the “Investors” section of the Company’s website at www.t2biosystems.com.
About T2 Biosystems
T2 Biosystems, a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. T2 Biosystems’ products include the T2Dx® Instrument, the T2Bacteria® Panel, the T2Candida® Panel, the T2Resistance® Panel, and the T2Biothreat™ Panel, and are powered by the proprietary T2 Magnetic Resonance (T2MR®) technology. T2 Biosystems has an active pipeline of future products, including the U.S. T2Resistance Panel, the Candida auris test, and the T2Lyme™ Panel. For more information, please visit www.t2biosystems.com.
Investor Contact:
Philip Trip Taylor, Gilmartin Group
philip@gilmartinIR.com
415-937-5406
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.